Is Compounded Tirzepatide Still Legal in 2026?

If you have been buying compounded tirzepatide — the cheaper, non-brand version sold by some telehealth platforms and pharmacies — the legal ground under it has shifted, and the marketing around it has not always kept up. The short version: the conditions that made mass-compounding of tirzepatide permissible ended in early 2025, and in 2026 the FDA moved to close one door more permanently. This page lays out the regulatory timeline precisely, because the details — which compounders, which legal pathway, what the latest FDA proposal actually does — are exactly where the confusion (and the misleading sales copy) lives. None of this is legal or medical advice; it is a sourced map of where things stand.

First, what "compounded" means and why a shortage mattered

Tirzepatide is FDA-approved only as Eli Lilly's branded products — Zepbound for obesity and Mounjaro for type 2 diabetes¹. There is no FDA-approved generic. "Compounded tirzepatide" is a custom-made preparation mixed by a pharmacy, not an FDA-approved finished drug, and the FDA does not verify its safety, effectiveness, or quality the way it does for the approved products².

Normally, US law sharply limits compounding a drug that is "essentially a copy" of an available FDA-approved product. The exception that opened the floodgates was the drug shortage: while tirzepatide was on the FDA's shortage list, both kinds of compounders had room to make it — 503A pharmacies (state-licensed, patient-specific) and 503B outsourcing facilities (larger, FDA-registered)². That shortage exception is the entire reason a compounded-tirzepatide industry sprang up — and it is also why its legal footing was always temporary.

The timeline: shortage resolved, then the grace period closed

Here is the sequence that matters, with the dates that get misquoted online.

October 2024 — shortage declared resolved. The FDA determined that the tirzepatide shortage was resolved². Once a drug is no longer in shortage, the legal basis for compounding "essentially a copy" of it falls away.

December 2024 — wind-down announced, with grace periods. Rather than enforce immediately, the FDA announced it would hold off briefly to avoid disrupting patients mid-treatment, giving each type of compounder a defined runway².

Early 2025 — the grace periods ended. Enforcement discretion for 503A state-licensed pharmacies ended on February 18, 2025, and for 503B outsourcing facilities on March 19, 2025². After those dates, the FDA stated it could take action against firms still making tirzepatide that is essentially a copy of the approved drug².

2026 — FDA moves to shut the 503B door permanently. In a Federal Register notice published May 1, 2026, the FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list — the list of bulk drug substances that outsourcing facilities are allowed to compound from when there is a demonstrated clinical need³. In plain terms: the FDA found no clinical need that the approved products fail to meet, and so proposed to keep these drugs off the list, which would bar 503B outsourcing facilities from compounding tirzepatide from bulk active ingredient. The agency opened a public comment period running through June 29, 2026³.

What this is — and what it is NOT

This is the part the sales copy gets wrong, so be precise:

• •It is NOT an FDA "approval" of compounded tirzepatide. The 2026 action is the opposite — a proposal to exclude tirzepatide from the substances 503B facilities may compound from in bulk³.
• •It is NOT a brand-new "ban" that starts the clock. The legal basis for routine compounding already lapsed in early 2025 when the shortage-era grace periods ended². The 2026 proposal would make the 503B exclusion durable, not invent a restriction from scratch.
• •It is a proposal with a comment period, not yet a final rule. As of mid-2026 the comment window runs to June 29, 2026, and the outcome is not finalized³.
• •503A pharmacies are a separate, murkier story. The 503B bulks-list proposal targets outsourcing facilities. State-licensed 503A pharmacies operate under different rules and still cannot, post-shortage, compound a drug that is "essentially a copy" of an available approved product regularly or in inordinate amounts². So 503A compounding of tirzepatide is legally precarious rather than cleanly permitted — narrow, genuinely patient-specific exceptions (for example a documented clinical need the approved product can't meet) are a different matter from the high-volume online model.

The honest summary: the era of broadly legal, mass-marketed compounded tirzepatide ended in early 2025, and the 2026 proposal is the FDA working to keep it closed — not to reopen it.

Why the FDA is tightening, not loosening: the safety signal

The regulatory direction is reinforced by a safety concern. Because compounded products are not FDA-verified, problems with dosing, sterility, and source ingredients have surfaced. A 2026 pharmacovigilance study analyzing the FDA Adverse Event Reporting System (FAERS) found a substantial volume of adverse-event reports tied to compounded GLP-1 receptor agonists, including serious events — a signal the authors used to argue that the safety profile of compounded versions cannot be assumed equivalent to the approved drugs⁴. The FDA itself has separately warned about dosing errors with compounded GLP-1 products (patients drawing up the wrong amount from multi-dose vials) and about products sold by unregulated sellers². None of this proves every compounded dose is dangerous, but it explains why the regulatory momentum runs toward exclusion rather than endorsement.

What this means if you take compounded tirzepatide

This is not a directive to stop anything abruptly — stopping or switching a prescription is a clinical decision — but it is a reason to ask sharper questions:

• •Ask your provider which pathway your product comes from (503A pharmacy vs 503B facility) and on what legal basis it is being compounded now that the shortage is resolved.
• •Be skeptical of "FDA-approved" or "FDA-cleared" claims on compounded tirzepatide — there is no FDA-approved generic, and the 2026 action is an exclusion proposal, not an approval¹³.
• •Weigh the cost savings against the unknowns in quality, dosing, and legal durability. For how the brand pricing and savings programs compare, see Zepbound cost and savings and does insurance cover Zepbound.
• •Know the alternatives. Lilly's own lower-cost single-dose vial program and the question of an oral version change the math; we cover the pill landscape in oral tirzepatide.

The honest bottom line

Compounded tirzepatide rode a shortage exception that the FDA closed: the shortage was declared resolved in October 2024, the wind-down was announced in December 2024, and the enforcement grace periods ended on February 18, 2025 (503A) and March 19, 2025 (503B)². In 2026, the FDA went further, proposing in a May 1 Federal Register notice to keep tirzepatide off the 503B bulks list — finding no clinical need — with comments open through June 29, 2026³. That is an exclusion, not an approval, and it sits on top of a safety signal from FAERS reports tied to compounded GLP-1 products⁴. So in 2026, broadly legal mass-compounded tirzepatide is largely a thing of the past, and the only FDA-verified tirzepatide remains the branded products¹. For the bigger evidence and access picture, start with our tirzepatide evidence guide and best tirzepatide overview.